Sign In
Buy MRNS
$0.550
+0 (+0%)
At Close: May 09, 2025
LOS ANGELES, CA / ACCESSWIRE / May 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceut
LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuti
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
09:31am, Wednesday, 08'th May 2024
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago.
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 08'th May 2024
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
08:00am, Thursday, 02'nd May 2024
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASD
LOS ANGELES, CA / ACCESSWIRE / April 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Marinus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MRNS
05:00am, Monday, 22'nd Apr 2024
NEW YORK, NY / ACCESSWIRE / April 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
LOS ANGELES, CA / ACCESSWIRE / April 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Investors who lost money on Marinus Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - MRNS
08:00am, Sunday, 21'st Apr 2024
NEW YORK, NY / ACCESSWIRE / April 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
LOS ANGELES, CA / ACCESSWIRE / April 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Marinus Pharmaceuticals, Inc. (MRNS)
04:50am, Friday, 19'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
03:45pm, Wednesday, 17'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
12:51pm, Tuesday, 16'th Apr 2024
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
